ArticleArchives of virology2025
Genome diversity and evolutionary understanding of Lassa virus: a holistic approach highlighting a potential target for cross-lineage vaccine development.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies on the genetic diversity of Lassa virus (LASV) have often relied on sequences containing undetermined nucleotides. In this study, we analyzed open reading frame (ORF) sequences free of undetermined nucleotides to assess LASV diversity with improved accuracy. The calculated pairwise identity was ≥ 68% for the polymerase, ≥ 74% for the nucleoprotein (NP), and ≥ 75% for the glycoprotein (GP) genes. LASV strains were classified into seven established lineages. Notably, lineage VI (represented by strain KT992435.1_KAK-428) exhibited phylogenetic relatedness to all other lineages, suggesting that it may retain ancestral traits. This observation underscores the potential evolutionary significance of its rodent host, Hylomyscus pamfi. A multiple sequence alignment of the GP gene revealed a unique codon insertion present only in lineages IV and V. The GP from these two lineages showed a predicted antigenicity score of 0.66, which is lower than the maximum scores observed in other lineages. Nonetheless, all lineage representatives were predicted to be non-allergenic and non-toxic and possessed a moderate density of B- and T-cell epitopes with ≥ 90% conservation. Considering the observed genetic divergence, antigenic variation, and epitope conservation, lineage VI (KAK-428) is proposed as a potential target for the development of a broadly protective LASV vaccine.
Indexed as
Identifiers
41284110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.